ClinicalTrials.gg
RecruitingNCT06836011Updated Feb 19, 2025

A Multicenter Study on Atrioventricular Regurgitation in Transthyretin Amyloid Cardiomyopathy: Definition, Prevalence, and Prognostic Impact.

An observational study in ATTR Amyloidosis With Cardiomyopathy, ATTR-CM and ATTR Amyloidosis Wild Type, sponsored by Medical University of Vienna. Recruiting at 8 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-19.

Sponsored by Medical University of Vienna · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
  • Started Jan 2025; still recruiting 1 year 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
600
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 63 studies in Mitral Valve Insufficiency with a site in Italy — 20 open to participants now, 28 under way, none of them phase 3. Mitral Valve Insufficiency · Italy.

Planned enrollment
9th of 33
600 · median 200
Started
2025
with 5 others
Observational
33 of 63
11 open now
Primary completion
2025-12
later than 10 of 27 live
Registered
58th of 63
by date
Lead sponsor
2 of 63
Medical University of Vienna

Among the 63 studies in Mitral Valve Insufficiency with a site in Italy, this one is the 9th largest by planned enrollment of the 33 observational ones that give a count, is one of 6 that started in 2025, is one of 33 observational ones, reaches primary completion later than 10 of the 27 other live ones, and was the 58th registered.

Mitral Valve Insufficiency

471 studies on the registry are indexed under Mitral Valve Insufficiency; 165 are open to participants now.

Browse Mitral Valve Insufficiency studies →

Open to participants now

20 of the 63 studies in Mitral Valve Insufficiency with a site in Italy are open now. Recruiting first, the newest first:

14 more — sign in →

All 20 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 121 Mitral Valve Insufficiency studies recruiting now, 100 (83%) set no upper age limit and 6 (5%) stop at 75 or younger; 12 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 63 studies in Mitral Valve Insufficiency with a site in Italy, or all of them as a file.
02

Study summary

The objective of this prospective registry study is to comprehensively characterize the prevalence, (semi-) quantitative parameters, and associated clinical outcomes of mitral (MR) and tricuspid regurgitation (TR) in patients diagnosed with transthyretin amyloid cardiomyopathy (ATTR-CM). The study further aims to develop and implement new grading standards for the quantitative assessment of regurgitation severity, tailored to the distinct hemodynamic profile of ATTR-CM. This approach seeks to address the limitations of current regurgitation severity classifications, which do not adequately reflect the unique pathophysiology of a restrictive phenotype as seen in ATTR-CM.

03

Conditions studied

  • ATTR Amyloidosis With Cardiomyopathy
  • ATTR-CM
  • ATTR Amyloidosis Wild Type
  • Mitral Regurgitation
  • Tricuspid Regurgitation

Keywords

  • ATTR-CM
  • ATTR amyloidosis
  • Tricuspid Regurgitation
  • Mitral Regurgitation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

This observational study will include patients diagnosed with transthyretin amyloid cardiomyopathy (ATTR-CM) from international specialized cardiac amyloidosis referral centers. The study population will encompass both wild-type and hereditary ATTR-CM patients, ensuring representation of diverse disease phenotypes. Data collection will be standardized across centers, with echocardiographic assessments performed in accordance with the dedicated study protocol. The inclusion of multiple international centers will enhance the generalizability of findings across different healthcare systems and patient populations.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of ATTR-CM according to current diagnostic criteria
  • Comprehensive baseline echocardiographic assessment, including (semi-)quantitative mitral and tricuspid regurgitation (MR/TR) parameters, performed within ±6 months of diagnosis
  • Age ≥ 18 years
  • Willingness to participate in the study and provide

Exclusion criteria

Exclusion Criteria:

  • Severe aortic valve disease requiring intervention
  • Inability to provide or participate in study follow-up
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
600 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. All-cause mortality

    Assessment of all-cause mortality in patients with ATTR-CM, stratified by baseline quantitative and semiquantitative measures of mitral and tricuspid regurgitation severity

    Time frame: up to 60 months

Secondary outcomes

  1. Cardiovscular mortality

    Time frame: up to 60 months

  2. Heart Failure Hospitalization

    Time to first heart failure hospitalization Rate of heart failure hospitalizations

    Time frame: up to 60 months

Other outcomes

  1. Progression of Atrioventricular Regurgitation

    Change in mitral and tricuspid regurgitation severity over time and its impact on clinical outcomes.

    Time frame: At 12 and 24 months follow-up

07

Study locations

8 of 8 sites recruiting
  • Medical University of Graz
    Graz, Styria 8010, Austria
    Recruiting
    • Nicolas D Verheyen, Res.Prof. Priv.-Doz. DDr. · Contactnicolas.verheyen@medunigraz.at · +43 (0)316 385 30173
    • Nicolas D Verheyen, Res.Prof. Priv.-Doz. DDr. · Principal investigator
  • Department of Internal Medicine II, Medical University of Vienna
    Vienna, 1090, Austria
    Recruiting
    • Christian Nitsche, Priv.-Doz. Dr., PhD · Contactchristian.nitsche@meduniwien.ac.at · +4314040048590
    • Christian Nitsche, Priv.-Doz. Dr., PhD · Principal investigator
    • Laurenz Hauptmann, Dr. · Sub investigator
  • Medizinische Klinik und Poliklinik I, Klinikum der Universitaet Muenchen, Ludwig-Maximilians-University
    Munich, Bayern 81377, Germany
    Recruiting
  • Department of Cardiology, University Hospital Frankfurt, Goethe University
    Frankfurt am Main, Hessen 60596, Germany
    Recruiting
  • Institute of Cardiology, ASST Spedali Civili di Brescia, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia
    Brescia, 25100, Italy
    Recruiting
    • Marianna Adamo, Assoc.-Prof. Dr. · Contactmariannaadamo@hotmail.com · 0000
    • Marianna Adamo, Assoc.-Prof. Dr. · Principal investigator
  • Cardiologic Centre, Azienda Ospedaliero Universitaria di Ferrara
    Ferrara, 44121, Italy
    Recruiting
  • Center for Diagnosis and Treatment of Cardiomyopathies, Cardiovascular Department, Azienda Sanitaria Universitaria Giuliano-Isontina (ASUGI), University of Trieste
    Trieste, 34100, Italy
    Recruiting
    • Marco Merlo, Prof. Dr. · Contactmarco.merlo79@gmail.com · +39 040 3994875
    • Marco Merlo, Prof. Dr. · Principal investigator
  • University Medical Center Utrecht
    Utrecht, 3450, Netherlands
    Recruiting
    • Marish I.F.J. Oerlemans, Ass. Prof. Dr. · Contactmoerlem4@umcutrecht.nl · 0000
    • Marish I.F.J. Oerlemans, Ass. Prof. Dr. · Principal investigator
    • Steven A Muller, Dr. · Sub investigator
08

References and documents

Publications

  • Dona C, Nitsche C, Koschutnik M, Heitzinger G, Mascherbauer K, Kammerlander AA, Dannenberg V, Halavina K, Rettl R, Duca F, Traub-Weidinger T, Puchinger J, Gunacker PC, Lamm G, Vock P, Lileg B, Philipp V, Staudenherz A, Calabretta R, Hacker M, Agis H, Bartko P, Hengstenberg C, Fontana M, Goliasch G, Mascherbauer J. Unveiling Cardiac Amyloidosis, its Characteristics, and Outcomes Among Patients With MR Undergoing Transcatheter Edge-to-Edge MV Repair. JACC Cardiovasc Interv. 2022 Sep 12;15(17):1748-1758. doi: 10.1016/j.jcin.2022.06.009. Epub 2022 Aug 22. PubMed 36008266 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Dec 2025, 11 months after the start.

Of 73 non-industry observational studies under Mitral Valve Insufficiency, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 192. This study's planned 11 months is below that.

Counting every sponsor, half of 85 studies reached it within 57 months; a quarter within 26 and three quarters within 192.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 14, 2025
First posted
Feb 19, 2025
StartActual
Jan 1, 2025
Primary completionEst.
Dec 31, 2025
CompletionEst.
Dec 31, 2026
Last update
Feb 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06836011
Responsible party
Christian Nitsche (Priv.-Doz. Dr. med. univ., PhD, Medical University of Vienna) — Principal investigator
First posted
Feb 19, 2025
Start date
Jan 1, 2025
Primary completion
Dec 31, 2025 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Feb 19, 2025

Study contacts

Christian Nitsche, Priv.-Doz. Dr., PhD
Contact
christian.nitsche@meduniwien.ac.at
+4314040048590
Laurenz Hauptmann, Dr.
Contact
Laurenz.hauptmann@meduniwien.ac.at
+4314040048590

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion